Pantaz - Instructions For The Use Of Tablets, Reviews, Price, Analogues Of The Drug

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Pantaz

Pantaz: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Pantaz

ATX code: A02BC02

Active ingredient: pantoprazole (Pantoprazole)

Manufacturer: Medley Pharmaceuticals, Ltd. (Medley Pharmaceuticals, Ltd.) (India)

Description and photo update: 2019-13-11

Pantaz is an antiulcer drug, a proton pump inhibitor, which reduces the secretion of hydrochloric acid.

Release form and composition

The drug is produced in the form of enteric-coated tablets: light yellow, round, biconvex, white core (10 pieces in blisters, in a cardboard box of 1, 3 or 10 blisters and instructions for use Pantaza).

1 tablet contains:

• active substance: pantoprazole sodium sesquihydrate - 45.2 mg, which is equivalent to 40 mg of pantoprazole;
• auxiliary components: sodium carbonate, mannitol, crospovidone, hydroxypropyl methylcellulose (hypromellose), calcium stearate;
• enteric coating: copolymer of methacrylic acid and methyl methacrylate (1 ÷ 1), macrogol 6000, dibutyl phthalate, titanium dioxide, hypromellose (hydroxypropyl methylcellulose), iron dye yellow oxide, purified talc.

Pharmacological properties

Pharmacodynamics

Pantaz is a drug that lowers the secretion of stomach glands. Its active ingredient, pantoprazole, is an inhibitor of the H ⁺ / K ⁺ -ATPase enzyme (hydrogen potassium adenosine triphosphatase), which acts as a proton pump in the parietal cells of the stomach, blocking the synthesis of hydrochloric acid in the final stage. The effect of the drug, regardless of the nature of the irritant, provides a decrease in the basal and stimulated secretion of hydrochloric acid, without affecting the motility of the gastrointestinal tract (GIT).

After a single oral administration in a dose of 20 mg, the effect occurs within 1 hour and reaches a maximum after 2–2.5 hours. The secretory activity after the withdrawal of pantoprazole is fully restored after 72–96 hours.

Pharmacokinetics

After oral administration, pantoprazole is rapidly absorbed from the gastrointestinal tract. The maximum concentration (C _max) in plasma is reached after 2–2.5 hours, and can range from 0.001 to 0.0015 mg / ml, including with prolonged use. The bioavailability of pantoprazole is 77%. Concomitant food intake may delay the onset of action of Pantaz, but the C _max, AUC (area under the concentration-time curve) or its bioavailability is not affected.

Plasma protein binding is about 98%, volume of distribution is about 0.15 l / kg, clearance is 0.1 l / h / kg.

Pantoprazole is metabolized almost completely in the liver with the formation of the main metabolite, desmethylpantoprazole, which is conjugated with sulfate and is determined in serum and urine. Pantoprazole exhibits an inhibitory effect on the CYP2C19 enzyme system.

The half-life (T _1/2) does not correlate with the duration of the therapeutic effect and is 1 hour, including with impaired renal function. T _{1/2 of the} main metabolite is approximately 1.5 hours.

The substance is excreted mainly in the form of metabolites through the kidneys - 80%, the rest - with bile.

In chronic renal failure (including patients on hemodialysis), dose adjustment is not required. Very small amounts of pantoprazole can be dialyzed.

In patients with class A and B cirrhosis according to the Child-Pugh classification, when taking pantoprazole in a daily dose of 20 mg, AUC increases 3-5 times compared with healthy individuals, C _max - 1.3 times, and T _1/2 is 3-6 hours

In elderly patients, the increase in AUC and C _{max is} insignificant and is not clinically significant.

Indications for use

• peptic ulcer of the stomach and duodenum, including for the purpose of prevention;
• gastroesophageal reflux disease (GERD), including erosive and ulcerative reflux esophagitis and symptoms (heartburn, pain when swallowing, regurgitation of acidic stomach contents) associated with GERD;
• Zollinger-Ellison syndrome;
• eradication of Helicobacter pylori - as part of combination therapy.

Contraindications

Absolute:

• dyspepsia of neurotic genesis;
• age up to 18 years;
• hypersensitivity to the components of the drug.

Pantaz should be taken with caution during pregnancy and lactation, with liver failure, the presence of risk factors for cyanocobalamin deficiency (vitamin B ₁₂), especially in patients with hypo- and achlorhydria.

Pantaz, instructions for use: method and dosage

Pantaz tablets are taken orally, before breakfast, swallowing whole (cannot be chewed or broken) and washed down with a small amount of liquid. If you need to take twice a day, the second dose should be taken before dinner.

Recommended daily dosage of Pantaza:

• peptic ulcer and duodenal ulcer, Zollinger-Ellison syndrome: 40–80 mg; the duration of the course for the treatment of stomach ulcers - 28–56 days, for scarring of duodenal ulcers - 14 days;
• reflux esophagitis: 20-40 mg; course duration from 28 to 56 days;
• eradication of Helicobacter pylori (as part of combination therapy): 20 mg 2 times a day in combination with amoxicillin (1000 mg 2 times a day) and clarithromycin (500 mg 2 times a day), or with metronidazole (500 mg 2 once a day) and clarithromycin (500 mg 2 times a day), or with amoxicillin (1000 mg 2 times a day) and metronidazole (500 mg 2 times a day); the duration of the course is 7-14 days.

The maximum daily dose of Pantaza for the treatment of patients in the elderly and with chronic renal failure is 40 mg.

The recommended dosing regimen for hepatic insufficiency: 40 mg 1 time in 2 days.

Side effects

• from the nervous system: often - headache; infrequently - visual impairment (blurred visual perception), dizziness;
• from the digestive system: often - flatulence, abdominal pain, constipation or diarrhea; infrequently - nausea, vomiting; rarely - dry mouth; very rarely - severe liver damage, jaundice without or with hepatic failure, increased activity of hepatic transaminases, gamma-glutamyltransferase (GGT);
• on the part of hematopoietic organs: very rarely - thrombocytopenia, leukopenia;
• from the immune system: very rarely - the development of anaphylactic reactions (including anaphylactic shock);
• allergic reactions: infrequently - itching, rash; very rarely - angioedema, urticaria, photosensitivity, Stevens-Johnson syndrome, Lyell's syndrome, erythema polymorphism;
• on the part of the musculoskeletal system: rarely - arthralgia; very rarely - myalgia;
• mental disorders: very rarely - hallucinations, disorientation, depression, confusion (more often in predisposed persons);
• from the genitourinary system: very rarely - interstitial nephritis;
• general disorders: very rarely - weakness, hyperthermia, peripheral edema, painful tension of the mammary glands, an increase in the concentration of triglycerides.

Overdose

Symptoms of a pantoprazole overdose in humans have not been established.

In case of intoxication, supportive and symptomatic therapy is recommended. The specific antidote is unknown.

special instructions

Pantaz should be prescribed only if the results of endoscopic studies (if necessary with a biopsy, especially for patients with stomach ulcers), confirming the absence of a malignant neoplasm. Since taking the drug can mask the symptoms of the tumor and delay the correct diagnosis. In the absence of a clinical effect after 1 month of pantoprazole therapy, the patient must undergo re-examination.

If severe side effects occur, Pantaz should be discontinued.

Against the background of the use of pantoprazole, the absorption of cyanocobalamin may decrease with hypo- and achlorhydria. Therefore, special attention should be paid to this when treating patients with risk factors for vitamin B ₁₂ deficiency or long-term use of the drug.

Long-term therapy with Pantaz, especially if it lasts more than 12 months, should be accompanied by regular monitoring of the patient's condition.

It should be borne in mind that a test for the determination of THC (tetrahydrocannabinol) in the urine of patients taking pantoprazole may give a false positive result.

Influence on the ability to drive vehicles and complex mechanisms

During the period of treatment with Pantaz, patients are advised to be careful when driving vehicles or other complex mechanisms due to the existing risk of developing such adverse events from the nervous system as blurred vision or dizziness.

Application during pregnancy and lactation

The use of Pantaz tablets during pregnancy and lactation is allowed only in cases where the therapeutic effect for the mother justifies the potential risks of the effect of pantoprazole on the fetus and child.

Pediatric use

The use of Pantaza at the age of 18 years is contraindicated due to the fact that the efficacy and safety of pantoprazole for the treatment of this category of patients has not been established.

With impaired renal function

When treating patients with chronic renal failure, the daily dose of Pantaza should not exceed 40 mg.

For violations of liver function

Pantaz should be used with caution to treat patients with hepatic impairment. The recommended dosing regimen for these patients: 40 mg once every 2 days. Do not exceed this dose.

Use in the elderly

When treating elderly patients, the daily dose of Pantaza should not exceed 40 mg.

Drug interactions

When taken simultaneously with Pantaz:

• ketoconazole, iron preparations and other drugs, the bioavailability of which depends on the pH (acidity) of the stomach: it should be borne in mind that pantoprazole reduces the absorption of drugs absorbed in an environment with acidic pH values;
• digoxin, diazepam, diclofenac, phenytoin, glibenclamide, carbamazepine, metoprolol, naproxen, nifedipine, theophylline, oral contraceptives, piroxicam, antacids, caffeine, ethanol: in combination with these drugs, clinically significant interactions do not occur;
• warfarin: there is a risk of interaction between pantoprazole and warfarin, which may result in a change in the INR (international normalized ratio). With concomitant therapy with coumarin anticoagulants, INR and prothrombin time should be regularly monitored;
• atazanavir, nelfinavir: it is recommended to avoid the combination of these drugs with pantoprazole due to the fact that proton pump inhibitors can lower their plasma concentration and weaken the effect of antiretroviral therapy.

Analogs

The analogues of Pantaza are Pantoprazole Canon, Pantoprazole-Akrikhin, Zipantola, Controlok, Krosacid, Panum, Peptazol, Pizhenum-sanovel, Puloref, Sanpraz, Ultera, etc.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 25 ° C, protected from moisture.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Pantaza

Reviews about Pantaza are positive. Patients report that with pain in the stomach caused by digestive problems, accompanied by heartburn and bitter taste in the mouth, taking the drug quickly eliminates all clinical manifestations. The advantages include high efficiency and good tolerance.

Price for Pantaz in pharmacies

The price of Pantaz, 40 mg enteric-coated tablets, per pack of 30 pcs., Can be approximately from 319 to 325 rubles.

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!